235 related articles for article (PubMed ID: 30325567)
1. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Crauwels HM; Baugh B; Van Landuyt E; Vanveggel S; Hijzen A; Opsomer M
Clin Pharmacol Drug Dev; 2019 May; 8(4):480-491. PubMed ID: 30412360
[TBL] [Abstract][Full Text] [Related]
3. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
4. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
[TBL] [Abstract][Full Text] [Related]
6. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
[TBL] [Abstract][Full Text] [Related]
7. Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Yamada H; Ikushima I; Nemoto T; Ishikawa T; Ninomiya N; Irie S
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):132-142. PubMed ID: 28581645
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Salama E; Hill L; Patel N; Best BM; Momper JD
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):389-392. PubMed ID: 34285156
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
11. EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Andrade A; Fuchs EJ; Marzinke MA; Abdul Massih S; Breakey J; Beselman S; McNicholl I; Hendrix CW
AIDS Res Hum Retroviruses; 2023 Jan; 39(1):38-43. PubMed ID: 36301928
[TBL] [Abstract][Full Text] [Related]
12. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
13. A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults.
Muccini C; Castagna A
Expert Rev Anti Infect Ther; 2023; 21(11):1167-1176. PubMed ID: 37800640
[TBL] [Abstract][Full Text] [Related]
14. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
15. Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.
Custodio JM; Chuck SK; Chu H; Cao H; Ma G; Flaherty J; Ling J; Kearney BP
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971607
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
18. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
19. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Cevik M; Orkin C
Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
[TBL] [Abstract][Full Text] [Related]
20. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
